8-K: Liquidia Settles All Litigation with United Therapeutics

Liquidia Corporation has reached a global settlement agreement with United Therapeutics Corporation, resolving all ongoing litigation and ensuring the continued availability of YUTREPIA for PAH patients.

Summary

• Liquidia Corporation has entered into a global settlement agreement with United Therapeutics Corporation (UTC) to resolve all ongoing litigation between the two companies.
• The settlement ensures that YUTREPIA (treprostinil) inhalation powder will remain available to patients with pulmonary arterial hypertension (PAH).
• Liquidia will pay a net amount of $175.0 million to UTC within 30 business days of the effective date, after accounting for a payment from UTC to Liquidia.
• Additionally, Liquidia will make a further payment of $145.4 million to UTC in two equal installments by January 31, 2027, and April 30, 2027.
• As part of the agreement, Liquidia will remove the PH-ILD indication from YUTREPIA's label and cease all marketing and promotion related to PH-ILD.
• The settlement also resolves antitrust and breach of contract proceedings related to the RareGen Litigation, with separate agreements made with Sandoz Inc. ($21.75 million), Henderson SPV, LLC ($19.05 million), and PBM RG Holdings, LLC ($19.45 million).
• Liquidia reported preliminary, unaudited YUTREPIA net product sales of $222.7 million for the third quarter of 2026, with total cash and cash equivalents of $396.1 million as of September 30, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, as it resolves significant litigation and provides operational clarity, despite the substantial settlement costs.

Positives

• Resolves all six ongoing lawsuits between Liquidia and United Therapeutics, providing significant legal and operational certainty.
• Ensures uninterrupted access to YUTREPIA for patients with Pulmonary Arterial Hypertension (PAH).
• Liquidia's CEO, Dr. Roger Jeffs, stated the company can now focus resources on growing the YUTREPIA brand and advancing its clinical programs.
• Preliminary Q3 2026 YUTREPIA net product sales reached $222.7 million.
• Company has $396.1 million in cash and cash equivalents as of September 30, 2026, expected to fund settlement obligations and ongoing investments without additional financing.
• Mutual releases are part of the settlement, meaning neither party admits liability.

Negatives

• The settlement requires significant financial outlays totaling approximately $380.7 million ($175M net to UTC + $145.4M installments + $60.3M to other parties).
• Liquidia has agreed to remove the PH-ILD indication from YUTREPIA's label and cease all related marketing and promotion.
• Liquidia will not appeal the U.S. District Court for the District of Delaware's ruling that claims 1 and 14 of U.S. Patent No. 11,826,327 are valid and infringed.

Risks

• United Therapeutics may assert patents against Liquidia's development programs or future products.
• The settlement agreement does not extend to indications other than PAH or to new treprostinil-containing products.
• The company's ability to meet settlement obligations while continuing to invest in business and clinical studies relies on ongoing sales and cash reserves.

Future Outlook

Liquidia expects to fund the settlement payments from ongoing YUTREPIA sales and cash on hand, without requiring additional financing. The company plans to continue advancing YUTREPIA and L606 clinical programs and exploring new treatments for other conditions.

Management Comments

• "We are always guided by our commitment to act in the best interests of patients in everything we do. Today's agreement fully resolves years of litigation and provides certainty to PAH patients that they can continue to access YUTREPIA..."
• "We can now focus our full attention and resources on further growing the YUTREPIA brand, with the goal of making it the prostacyclin therapy of choice in PAH..."
• "We are confident this settlement is in the best interests of our patients and shareholders and in our ability to meet the settlement obligations while continuing to invest in the business."
• "We expect to rebuild our cash position and fund our planned clinical studies without requiring additional financing."

Industry Context

StockSavvy.ai notes that this settlement is a significant event in the pulmonary hypertension market, which is characterized by intense patent litigation and competition among therapeutic options. Resolving this long-standing dispute with a major competitor like United Therapeutics allows Liquidia to focus on commercial growth and pipeline development, a common strategic shift after major legal battles.

Comparison to Industry Standards

• The settlement amount of approximately $380.7 million is substantial, reflecting the high stakes in pharmaceutical patent litigation. For comparison, major patent disputes in the pharmaceutical industry often involve settlements in the hundreds of millions or even billions of dollars, depending on the drug's market potential and the strength of the patent claims.
• The structure of the payments, with a significant upfront net payment and subsequent installments, is a common feature in large settlement agreements, allowing the paying party to manage cash flow.
• The decision to remove a specific indication (PH-ILD) from a product label is a strategic move often employed to resolve patent disputes, particularly when the patent holder has strong claims related to that indication. This is a standard practice to de-escalate litigation and secure market access for the core indication (PAH).

Legal Proceedings

• Resolution of six ongoing lawsuits between Liquidia and United Therapeutics, including patent infringement, trade secret misappropriation, breach of contract, and antitrust violations.
• The settlement includes the dismissal with prejudice of specific cases: United Therapeutics Corporation v. Liquidia Technologies, Inc., C.A. No. 1:23-cv-00975; United Therapeutics Corporation v. Liquidia Technologies, Inc., C.A. No. 1:25-cv-00368; Liquidia Technologies, Inc. v. United Therapeutics Corporation, C.A. No. 1:25-cv-00299; United Therapeutics Corporation and Lung Biotechnology PBC v. Liquidia Technologies, Inc. and Robert Roscigno, No. 21CVS004094-310; United Therapeutics Corporation and Lung Biotechnology PBC v. Robert Roscigno and Liquidia Technologies, Inc., No. 24CVS3755; and Sandoz Inc. and RareGen, LLC v. United Therapeutics Corporation and Smiths Medical ASD, Inc., No. 2:19-cv-1070, and related appeals.

Related Party Transactions

• The PBM Agreement involves PBM RG Holdings, LLC, which is controlled by Paul B. Manning (a stockholder and board member), Roger Jeffs (CEO and board member), Damian deGoa (board member), and Russell Schundler (General Counsel). The PBM Agreement was reviewed and approved by disinterested members of the Board.

Stakeholder Impact

• Shareholders: The settlement resolves a major legal uncertainty, potentially leading to a more stable stock price, but the significant payment obligations will impact cash reserves and profitability.
• Patients: Continued access to YUTREPIA for PAH patients is ensured. The removal of the PH-ILD indication means patients with this condition will no longer be able to use YUTREPIA for that specific indication.
• Creditors: The company's cash position and ability to meet settlement obligations are crucial for maintaining confidence among creditors.

Next Steps

• File stipulations to dismiss all pending litigation between Liquidia and UTC with prejudice.
• Liquidia to file a supplement with the FDA to remove the PH-ILD indication from YUTREPIA's label.
• Liquidia to cease all marketing, advertising, promotion, and detailing of YUTREPIA for the treatment of PH-ILD.
• Make the net payment of $175.0 million to UTC within 30 business days.
• Make the first installment payment of $72.7 million to UTC on or before January 31, 2027.
• Make the second installment payment of $72.7 million to UTC on or before April 30, 2027.
• Continue to advance YUTREPIA and L606 clinical programs.
• Provide a broader update on YUTREPIA's performance, financial position, and pipeline priorities on the Q3 2026 earnings call in November.

Key Dates

Recommendation

The settlement resolves significant litigation, removing a major overhang and allowing the company to focus on growth. However, the substantial financial commitment and the removal of a product indication temper an aggressive buy recommendation. The company's ability to execute on its growth strategy and manage its cash position will be key factors for future performance.

Keywords

Settlement Agreement, Litigation, YUTREPIA, Pulmonary Arterial Hypertension, United Therapeutics, PH-ILD, Antitrust Litigation, Treprostinil